Back to top
more

CareDx (CDNA)

(Delayed Data from NSDQ)

$14.77 USD

14.77
1,675,021

+0.47 (3.29%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $14.78 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 245)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Do Options Traders Know Something About CareDx Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to CDNA stock based on the movements in the options market lately.

Zacks Equity Research

Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings

by Zacks Equity Research

The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and -4.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

CareDx (CDNA) Tops Q1 Earnings Estimates

by Zacks Equity Research

CareDx (CDNA) delivered earnings and revenue surprises of 50% and 0.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Elevance Health (ELV) Soars 5.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Here's Why Community Health's Florida Divestiture Matters

by Zacks Equity Research

Offloading the Punta Gorda facility is expected to remove uncertainty tied to restoration costs and revenue losses for CYH.

Zacks Equity Research

New Strong Buy Stocks for February 27th

by Zacks Equity Research

BCS, CDNA, PGR, EZPW and EVER have been added to the Zacks Rank #1 (Strong Buy) List on February 27, 2025.

Zacks Equity Research

CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Pediatrix Medical Group (MD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 37.84% and 3.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CareDx (CDNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 42.3% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Best Momentum Stocks to Buy for January 30th

by Zacks Equity Research

OBK, BBCP and CDNA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 30, 2024.

Zacks Equity Research

New Strong Buy Stocks for January 30th

by Zacks Equity Research

BBCP, SDVKY, OBK, CDNA and NVAX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024.

Zacks Equity Research

Is CareDx (CDNA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how CareDx (CDNA) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Zacks Equity Research

Best Momentum Stocks to Buy for January 21st

by Zacks Equity Research

CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.

Zacks Equity Research

New Strong Buy Stocks for January 21st

by Zacks Equity Research

CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025.

Zacks Equity Research

Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?

by Zacks Equity Research

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Implied Volatility Surging for CareDx (CDNA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to CareDx (CDNA) stock based on the movements in the options market lately.

Zacks Equity Research

Here's Why You Should Add Ensign Group Stock to Your Portfolio Now

by Zacks Equity Research

ENSG should benefit from expanding facilities and growing footprint, leading to higher service revenues in the future.

Zacks Equity Research

Ensign Expands Footprint With Buyout of Eight Healthcare Facilities

by Zacks Equity Research

ENSG agrees to buy eight healthcare facilities from Providence Home and Community Care, expanding its footprint.

Zacks Equity Research

Molina Healthcare Expands Dual Eligible Services in Michigan, Idaho

by Zacks Equity Research

MOH secures key contracts in Michigan and Idaho to expand services for dual-eligible populations, driving growth and strengthening its role in integrated care solutions.

Zacks Equity Research

Ensign Group Rewards Shareholders With 4.2% Dividend Hike

by Zacks Equity Research

ENSG hikes quarterly dividend by 4.2%, maintaining its record of raising dividends for the past 22 years.

Zacks Equity Research

Centene Unveils Its 2025 Guidance, Reaffirms 2024 Outlook

by Zacks Equity Research

CNC expects robust growth in its Medicaid, Marketplace and Medicare businesses. This is likely to be driven by rate increases, rising uninsured individuals and dual expansions.

Zacks Equity Research

Community Health to Divest North Carolina Hospital for $280M

by Zacks Equity Research

CYH is selling the 123-bed facility in Mooresville to Duke Health.